Navigating tariffs and diplomacy: the future of India-US pharmaceutical trade
Pharmaceutical Technology
JUNE 18, 2025
Amid President Donald Trump’s stated desire to sharply reduce drug prices on the US market, India has also proposed to supply generic medicines at between 20% and 25% of the current reference branded prices, for three years after originator patent expiry. For a demo or further information, please contact us here.
Let's personalize your content